Chemotherapy-induced peripheral neurotoxicity

Cavaletti, Guido; Marmiroli, P

doi:10.1097/wco.0000000000000234

Cited by 180 publications

(156 citation statements)

References 59 publications

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…68,69 A further complicating factor is the phenomenon of 'coasting', whereby the symptoms of peripheral neuropathy may continue to progress or even first appear following termination of treatment. 6 Coasting is commonly associated with platinum-derived agents, although it may be seen with other chemotherapeutics such as bortezomib. 70 …”

Section: Clinical Featuresmentioning

confidence: 99%

“…Causes of peripheral neuropathy in cancer vary, but it can result from direct effects of the tumour itself as observed in paraneoplastic polyneuropathies, 5 or from its treatment with chemotherapeutic agents, termed chemotherapy-induced peripheral neuropathy (CIPN). 6 Although chemotherapeutic neurotoxicity may affect the central nervous system, peripheral sensory neuropathy is most prevalent, affecting from 10% to 100% of patients depending on factors such as the presence of co-morbidities, choice of chemotherapeutic agent and cumulative dose. 7,8 CIPN represents a major concern in the management of malignancy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pain in cancer survivors

Brown

Ramirez

Farquhar-Smith

2014

British Journal of Pain

View full text Add to dashboard Cite

Cancer and its treatment exert a heavy psychological and physical toll. Of the myriad symptoms which result, pain is common, encountered in between 30% and 60% of cancer survivors. Pain in cancer survivors is a major and growing problem, impeding the recovery and rehabilitation of patients who have beaten cancer and negatively impacting on cancer patients' quality of life, work prospects and mental health. Persistent pain in cancer survivors remains challenging to treat successfully. Pain can arise both due to the underlying disease and the various treatments the patient has been subjected to. Chemotherapy causes painful chemotherapy-induced peripheral neuropathy (CIPN), radiotherapy can produce late effect radiation toxicity and surgery may lead to the development of persistent post-surgical pain syndromes. This review explores a selection of the common causes of persistent pain in cancer survivors, detailing our current understanding of the pathophysiology and outlining both the clinical manifestations of individual pain states and the treatment options available.

show abstract

Section: Clinical Featuresmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Pain in cancer survivors

Brown

Ramirez

Farquhar-Smith

2014

British Journal of Pain

View full text Add to dashboard Cite

show abstract

“…18 Patients experiencing this side effects would require reduction or cessation of the chemotherapy. 11,19,20 Worst case that could happen is increase in cancerrelated morbidity and mortality. The frequency and severity of the sideeffects depend very much on the dose, duration and schedule of the chemotherapy used.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of vincristine induced-peripheral neuropathy among Sudanese cancer patients

Imam¹,

Ibrahim²,

Palaian³

et al. 2016

JYP

View full text Add to dashboard Cite

Background: Increasing clinical evidence suggests treatment of cancer with neurotoxic agents results in some degree of peripheral neuropathy. Objective: The main objective of the study was to evaluate vincristine induced peripheral neuropathy among Sudanese cancer patients. Methods: A descriptive cross-sectional study was carried out at Radiation and Isotopes Center, Khartoum State, Sudan. All patients suffering from cancer with an age of 18 to 65 years were reviewed. A self-developed data collection form was used to collect the demographic data; drug use history; medical diseases; and vincristine cycles. The World Health Organization criteria were used to grade the side-effects. Data was collected for a period of two months and were analyzed descriptively. Results: Out of 78 patients reviewed, majority were females (n=47, 60.3%). Most of the patients were in the age group of 18-30 (n=27, 34.6%) and 51-60 (n=27, 34.6%) years. Twenty six (33.3%) of the patients took analgesic and 15.3% (n=12) experienced hypertension. Most of the patients went through more than 6 cycles of therapy with vincristine (n=24, 30.9%). Our study showed that 'altered bowel function (i.e constipation)' was the most important neuropathic change, which occurred in 62 (79.5%) of the patients who received vincristine. The second common neuropathic change was the 'lack of ability to go upstairs un-aided', which occurred in 37 (47.4%) of patients receiving vincristine. Majority of the patients (n=37, 47.5%) showed mild paresthesia as graded by the 'WHO grading scale'. Conclusion: More than three-fourth of the cancer patients experienced vincristine induced peripheral neuropathy. Healthcare professionals need some understanding regarding medical management that may decrease occurrence of neuropathy and a better planning and implementing special care for patients at risk.

show abstract

“…apy protocols has not been established". There is also need for healthcare professionals to measure the effectiveness of interventions such as exercise, patient education and self-care strategies in patients with CIPN, and to develop and/or participate in well-designed clinical trials on prevention and management of symptoms [158].…”

Section: Discussionmentioning

confidence: 99%

Assessment and Treatment of Chemotherapy-induced Peripheral Neuropathy- a Physical Therapy Perspective

Kumar

Jamwal

2015

GJCT

View full text Add to dashboard Cite

Chemotherapy is recognized as a mainline treatment for all types of cancer, and its most debilitating and dose-limiting complication is Chemotherapy-induced peripheral neuropathy (CIPN), the mechanisms of nerve damage of which depends upon the specific chemotherapeutic agent used. Use of non-invasive treatment methods such as physical therapy may provide a valuable therapeutic adjunctive option in patients with CIPN. Physical therapy treatment methods had been shown to produce effective symptom control and enhance quality of life in palliative care. A detailed evidence-based update of literature is provided under evaluation and management of CIPN with a special perspective of physical therapy management using a proposed clinical reasoning-based treatment decision making algorithm so that an Ã¢â‚¬Ëœout of the boxÃ¢â‚¬â„¢ self-reflective evidence-informed critical thinking process is applied along a collaborative multidisciplinary biopsychosocial approach.Ã‚Â Keywords: Chemotherapy-induced neurotoxicity; Chemotherapy-induced neuropathy; Physical therapy; Palliative rehabilitation

show abstract

Chemotherapy-induced peripheral neurotoxicity

Cited by 180 publications

References 59 publications

Pain in cancer survivors

Pain in cancer survivors

Prevalence of vincristine induced-peripheral neuropathy among Sudanese cancer patients

Assessment and Treatment of Chemotherapy-induced Peripheral Neuropathy- a Physical Therapy Perspective

Contact Info

Product

Resources

About